Back to Search
Start Over
General information for patients and carers considering haematopoietic stem cell transplantation (HSCT) for severe autoimmune diseases (ADs) : A position statement from the EBMT Autoimmune Diseases Working Party (ADWP), the EBMT Nurses Group, the EBMT Patient, Family and Donor Committee and the Joint Accreditation Committee of ISCT and EBMT (JACIE)
- Source :
- Bone Marrow Transplantation, 54(7), 933. Nature Publishing Group, Bone Marrow Transplantation, Bone Marrow Transplantation, Nature Publishing Group, 2019, ⟨10.1038/s41409-019-0430-7⟩, Recercat: Dipósit de la Recerca de Catalunya, Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya), Dipòsit Digital de Documents de la UAB, Universitat Autònoma de Barcelona, Recercat. Dipósit de la Recerca de Catalunya, instname
- Publication Year :
- 2019
-
Abstract
- International audience; Over the last 20 years, haematopoietic stem cell transplantation (HSCT) has been used to treat patients with severe autoimmune and inflammatory diseases whose response to standard treatment options has been limited, resulting in a poor long-term prognosis in terms of survival or disability. The vast majority of patients have received autologous HSCT where an increasing evidence-base supports its use in a wide range of autoimmune diseases, particularly relapsing remitting MS, systemic sclerosis and Crohn’s disease. Compared with standard treatments for autoimmune diseases, HSCT is associated with greater short-term risks, including a risk of treatment-related mortality and long-term complications. There is a need for a careful appraisal of potential benefits and risks by disease and transplant specialists working closely together with patients and carers to determine individual suitability for HSCT. HSCT should be conducted in accredited transplant centres with robust arrangements for long-term follow-up with both disease and transplant specialists. The aim of this open-access position statement is to provide plainly worded guidance for patients and non-specialist clinicians considering HSCT for an autoimmune disease, especially when treatment abroad is being considered. Recent technical publications in the field have been referenced to support the statement and provide more detail for clinicians advising patients.
- Subjects :
- medicine.medical_specialty
Autoimmune diseases
MEDLINE
Disease
Stem cells
Hospitals, Special
Transplantation, Autologous
Accreditation
03 medical and health sciences
0302 clinical medicine
Risk Factors
Medicine
Humans
Intensive care medicine
030203 arthritis & rheumatology
Autoimmune disease
Transplantation
business.industry
Standard treatment
Hematopoietic Stem Cell Transplantation
Hematology
medicine.disease
Tissue Donors
3. Good health
Haematopoiesis
surgical procedures, operative
Caregivers
030220 oncology & carcinogenesis
Perspective
[SDV.IMM]Life Sciences [q-bio]/Immunology
Stem cell
business
Subjects
Details
- Language :
- English
- ISSN :
- 02683369
- Database :
- OpenAIRE
- Journal :
- Bone Marrow Transplantation, 54(7), 933. Nature Publishing Group, Bone Marrow Transplantation, Bone Marrow Transplantation, Nature Publishing Group, 2019, ⟨10.1038/s41409-019-0430-7⟩, Recercat: Dipósit de la Recerca de Catalunya, Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya), Dipòsit Digital de Documents de la UAB, Universitat Autònoma de Barcelona, Recercat. Dipósit de la Recerca de Catalunya, instname
- Accession number :
- edsair.doi.dedup.....15a07ba7de2c03b1b58b3766f0ca5e8a